Because neither the CRABP-II- nor the FABP5-mediated RA signaling pathway is the key determinant of RA sensitivity in glioblastoma cells, it would be worthwhile to search for other RA-related factors that indicate RA sensitivity to enable reliable anti-glioblastoma therapy. Here, FABP5 is linked to glioblastoma.